FindTrial
Sign In

TACE combined with CT-guided iodine-125 seeds implantation versus TACE alone for hepatocellular carcinoma with portal vein tumor thrombus: a randomized controlled study

TACE combined with CT-guided iodine-125 seeds implantation versus TACE alone for hepatocellular carcinoma with portal vein tumor thrombus: a randomized controlled study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-15006137
Enrollment
Unknown
Registered
2015-03-23
Start date
2015-03-24
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

A:TACE combined with iodine-125 seeds implantation
B:TACE alone

Sponsors

the Third Affiliated Hospital of Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Imaging demonstrating type I or II PVTT, non-obstructing type III PVTT, or obstructive type III PVTT with multiple collateral vessels; 2. Child-Pugh class A or B; and 3. Eastern Cooperative Group performance status (ECOG) score of 0-2.

Exclusion criteria

Exclusion criteria: 1. Extrahepatic metastasis; 2. type IV PVTT; 3. Patients with surgery, local-regional therapies (radiofrequency ablation), or liver transplantation; 4. patients with previously sorafenib therapy, systemic chemotherapy, intra-arterial chemoinfusion, or TACE; and 5. had serious medical comorbidities.

Design outcomes

Primary

MeasureTime frame
Time to progression;overall survival;—

Countries

China

Contacts

Public ContactZhu Kangshun, Shan Hong
zhksh010@163.com+86 20 85252066

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026